252 related articles for article (PubMed ID: 18341638)
1. The effect of anti-CD40 ligand in immune thrombocytopenic purpura.
Patel VL; Schwartz J; Bussel JB
Br J Haematol; 2008 May; 141(4):545-8. PubMed ID: 18341638
[TBL] [Abstract][Full Text] [Related]
2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS
Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056
[TBL] [Abstract][Full Text] [Related]
4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
6. [CD 40 L blockade as a novel treatment for chronic ITP refractory to corticosteroids and splenectomy].
Kuwana M
Rinsho Ketsueki; 2003 Feb; 44(2):82-9. PubMed ID: 12692980
[No Abstract] [Full Text] [Related]
7. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.
Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M
Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945
[TBL] [Abstract][Full Text] [Related]
8. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
[TBL] [Abstract][Full Text] [Related]
9. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura.
Kuwana M; Nomura S; Fujimura K; Nagasawa T; Muto Y; Kurata Y; Tanaka S; Ikeda Y
Blood; 2004 Feb; 103(4):1229-36. PubMed ID: 14551140
[TBL] [Abstract][Full Text] [Related]
10. [Alteration and biological significance of peripheral dendritic cells in patients with chronic idiopathic thrombocytopenic purpura].
Ling Y; Cao XS; Yu ZQ; Qiu GQ; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):187-91. PubMed ID: 18788620
[TBL] [Abstract][Full Text] [Related]
11. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
Kuwana M; Iki S; Urabe A
Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
13. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
14. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
Delgado J; Bustos JG; Jimenez-Yuste V; Hernandez-Navarro F
Haematologica; 2002 Feb; 87(2):215-6. PubMed ID: 11836172
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA
Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
[TBL] [Abstract][Full Text] [Related]
18. Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy.
Andersson PO; Wadenvik H
Expert Rev Mol Med; 2004 Nov; 6(24):1-17. PubMed ID: 15538954
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
20. Induction of T-cell tolerance in a patient with idiopathic thrombocytopenic purpura by single injection of humanized monoclonal antibody to CD40 ligand.
Nomura S; Kuwana M; Ikeda Y
Autoimmunity; 2003 Aug; 36(5):317-9. PubMed ID: 14567562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
